Decitabine combined with chemotherapy in treatment of relapsed T lymphoblastic lymphoma/leukemia with TP53 mutation after allogeneic hematopoietic stem cell transplantation: report of 1 case and review of literature
10.3760/cma.j.cn115356-20220108-00010
- VernacularTitle:地西他滨联合化疗治疗伴TP53突变T淋巴母细胞淋巴瘤/白血病异基因造血干细胞移植后复发1例并文献复习
- Author:
Xiao YANG
1
;
Qingya CUI
;
Feng CHEN
;
Wei CUI
;
Haiping DAI
;
Jian ZHANG
;
Li YAO
;
Huiying QIU
;
Xiaming ZHU
;
Depei WU
;
Xiaowen TANG
Author Information
1. 苏州大学附属第一医院血液科 江苏省血液研究所 国家血液系统疾病临床医学研究中心 血液学协同创新中心，苏州 215006
- Keywords:
Precursor T-cell lymphoblastic leukemia-lymphoma;
Decitabine;
TP53 gene;
Recurrence;
Hematopoietic stem cell transplantation
- From:
Journal of Leukemia & Lymphoma
2022;31(7):419-422
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the efficacy and safety of decitabine combined with chemotherapy in treatment of relapsed/refractory T lymphoblastic lymphoma/leukemia (T-LBL/ALL) with TP53 mutation.Methods:The clinical data of a T-LBL/ALL patient with TP53 mutation who had recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) treated with decitabine combined with chemotherapy in the First Affiliated Hospital of Soochow University in June 2018 were retrospectively analyzed and the relevant literature was reviewed.Results:The patient, a 42-year-old male, diagnosed as T-LBL/ALL with TP53 mutation by comprehensive examination underwent sibling-matched donor allo-HSCT after a second complete remission. The patient relapsed 8 months later and was treated with decitabine combined with CLAG regimen to achieve complete remission again. And then, he had leukemia-free survival until now through maintenance treatment with decitabine.Conclusion:Decitabine combined with chemotherapy may be a safe and effective treatment option for relapsed T-LBL/ALL patients with TP53 mutation after allo-HSCT.
